TWI609686B - 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 - Google Patents
使用馬賽替尼治療以預測因子所識別的癌症患者亞群 Download PDFInfo
- Publication number
- TWI609686B TWI609686B TW102136110A TW102136110A TWI609686B TW I609686 B TWI609686 B TW I609686B TW 102136110 A TW102136110 A TW 102136110A TW 102136110 A TW102136110 A TW 102136110A TW I609686 B TWI609686 B TW I609686B
- Authority
- TW
- Taiwan
- Prior art keywords
- pain
- treatment
- patient
- patients
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214 | 2012-10-04 | ||
| ??12306214.3 | 2012-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201414475A TW201414475A (zh) | 2014-04-16 |
| TWI609686B true TWI609686B (zh) | 2018-01-01 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102136110A TWI609686B (zh) | 2012-10-04 | 2013-10-04 | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (enExample) |
| EP (1) | EP2903616B8 (enExample) |
| JP (1) | JP6234466B2 (enExample) |
| KR (1) | KR102149483B1 (enExample) |
| CN (1) | CN104968347A (enExample) |
| AR (1) | AR092899A1 (enExample) |
| AU (1) | AU2013326463B2 (enExample) |
| BR (1) | BR112015007144A2 (enExample) |
| CA (1) | CA2886979C (enExample) |
| DK (1) | DK2903616T3 (enExample) |
| EA (1) | EA037368B1 (enExample) |
| ES (1) | ES2656640T3 (enExample) |
| IL (1) | IL238107B (enExample) |
| MX (1) | MX369999B (enExample) |
| NZ (1) | NZ706420A (enExample) |
| SG (1) | SG11201502626PA (enExample) |
| SI (1) | SI2903616T1 (enExample) |
| TW (1) | TWI609686B (enExample) |
| WO (1) | WO2014053650A1 (enExample) |
| ZA (1) | ZA201503054B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049377A1 (en) * | 2013-10-04 | 2015-04-09 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| MX2016014574A (es) * | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| WO2016062286A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 脱克钙药物在用于制备治疗癌症的医药组合物中的用途 |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| RU2754369C2 (ru) | 2016-03-02 | 2021-09-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения |
| PT3240538T (pt) * | 2016-03-25 | 2021-12-07 | Ab Science | Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| EP3571200B8 (en) | 2017-01-17 | 2022-08-03 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| KR20240110997A (ko) * | 2017-02-01 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| WO2019152719A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| WO2020092240A1 (en) * | 2018-10-29 | 2020-05-07 | Northwestern University | Big data-driven personalized management of chronic pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US12509456B2 (en) | 2019-03-11 | 2025-12-30 | Deciphera Pharmaceuticals, Llc | Solid state forms of ripretinib |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| DK4084779T3 (da) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | Sammensætninger af 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro- 1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylurea |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375342T1 (de) | 2002-08-02 | 2007-10-15 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| EP1913160A2 (en) * | 2005-07-29 | 2008-04-23 | Bayer Healthcare LLC | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| WO2008115300A1 (en) * | 2006-12-01 | 2008-09-25 | Apocell, Inc. | C-kit phosphorylation in cancer |
| JP2010515708A (ja) | 2007-01-12 | 2010-05-13 | アブ サイエンス | 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療 |
| EP2118099B1 (en) | 2007-02-13 | 2011-07-06 | AB Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
| US20120264639A1 (en) | 2009-11-04 | 2012-10-18 | Jen Jen Yeh | Methods and compositions for predicting survival in subjects with cancer |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014053650A1 (en) | 2014-04-10 |
| EP2903616A1 (en) | 2015-08-12 |
| IL238107B (en) | 2018-03-29 |
| EA037368B1 (ru) | 2021-03-19 |
| US10238649B2 (en) | 2019-03-26 |
| EP2903616B8 (en) | 2018-02-07 |
| AU2013326463A1 (en) | 2015-04-16 |
| ES2656640T3 (es) | 2018-02-27 |
| SG11201502626PA (en) | 2015-05-28 |
| SI2903616T1 (en) | 2018-02-28 |
| BR112015007144A2 (pt) | 2017-12-12 |
| AU2013326463B2 (en) | 2018-01-18 |
| ZA201503054B (en) | 2016-11-30 |
| MX369999B (es) | 2019-11-28 |
| KR20150092739A (ko) | 2015-08-13 |
| TW201414475A (zh) | 2014-04-16 |
| CA2886979A1 (en) | 2014-04-10 |
| AR092899A1 (es) | 2015-05-06 |
| CA2886979C (en) | 2021-01-05 |
| MX2015004264A (es) | 2015-10-12 |
| DK2903616T3 (da) | 2018-01-29 |
| EA201500373A1 (ru) | 2016-02-29 |
| NZ706420A (en) | 2018-08-31 |
| US20150272945A1 (en) | 2015-10-01 |
| JP2015532296A (ja) | 2015-11-09 |
| CN104968347A (zh) | 2015-10-07 |
| EP2903616B1 (en) | 2017-12-13 |
| KR102149483B1 (ko) | 2020-08-28 |
| JP6234466B2 (ja) | 2017-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI609686B (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Schuler et al. | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial | |
| JP2025179063A (ja) | 素行障害の診断及び治療方法 | |
| Hata et al. | Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| KR20180134347A (ko) | 암의 진단 및 치료 방법 | |
| KR20150131312A (ko) | 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료 | |
| EP3638242A1 (en) | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| US20160208328A1 (en) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same | |
| Thomas et al. | PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant | |
| Harrison et al. | Treatment of Glioblastoma in the Elderly | |
| Antonacopoulou et al. | Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? | |
| JP2017511341A (ja) | Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ | |
| US20200071765A1 (en) | Cancer treatments and methods of selecting same | |
| US9808469B2 (en) | Antitumor activity of multi-kinase inhibitors in triple negative breast cancer | |
| Li et al. | [Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta‐Analysis | |
| Bolzacchini et al. | Safety report of TAS-102 in a patient with reduced DPD activity | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| Yi et al. | Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors | |
| Nazarov et al. | Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells | |
| JP2025507955A (ja) | 癌の治療のための精密療法 | |
| Hill | Biological mechanisms of disease relapse in childhood medulloblastoma | |
| Mateos | Evaluation of risk of acute lymphoblastic leukaemia treatment-related side-effects: the ERASE study | |
| Journe et al. | 254 cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines | |
| Haegebarth et al. | Synergistic Activity of IDH1 Inhibitor BAY1436032 with Azacitidine in |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |